Inhibitors for Metastasized Breast Cancers
Background:
The National Cancer Institute's Laboratory of
Molecular Pharmacology is seeking statements of capability or
interest from parties interested in collaborative research to
further develop, evaluate, or commercialize histone deacetylase
(HDAC) inhibitor (HDI) for breast cancer brain
metastases.
The incidence of brain metastasis in breast
cancer patients is increasing, as chemo- and molecular therapies
improve systemic survival benefits. The majority of breast cancer
deaths in the United States will be due to metastases of the
primary breast cancer, with approximately 10%-20% of women with
metastatic breast cancer developing brain metastasis. The median
survival after diagnosis of brain metastasis is only one year. Few
treatment options are available for cancer patients with central
nervous system (CNS) metastasis because the blood-brain barrier
severely limits drug access. There is a need for the development of
new therapies to treat CNS metastases.
Technology:
This invention provides a method of treating
CNS metastatic disease originating from the breast and/or other
organs with a histone deacetylase (HDAC) inhibitor (HDI). The HDI
can be any HDI that is capable of crossing the blood-brain barrier
(BBB) such as vorinostat. Use of vorinostat to treat CNS metastases
is particularly attractive because the drug has been approved by
the FDA and will require less testing for use in other indications.
In addition to CNS metastases resulting from breast cancer, the
methods described in this invention have the potential to be
effective in treating metastases resulting from colon, liver, lung,
and prostate cancers.
Further R&D Needed:
- Mechanistic studies are underway to delineate mechanism of
action
- Combination studies are needed with radiation and other
agents
R&D Status:
In vivo animal model data available with vorinostat
IP Status:
U.S. Provisional Application No.
60/891,856 filed 02 Feb 2007
Value Proposition:
- There are no chemotherapeutic agents with demonstrated efficacy
against brain metastases of breast cancer. This is particularly
true for the triple negative subset of breast cancers. The
preclinical data which form the basis of this patent indicate that
vorinostat and other agents may be capable of preventing the
outgrowth of this disease.
- Method to treat CNS metastasis resulting from breast and other
forms of cancer.
Contact
Information:
John D. Hewes, Ph.D., NCI Technology
Transfer Center
Phone:
301-435-3121
E-mail: Hewesj@mail.nih.gov
Reference: #571 LF
Posted 11/06/2007
This opportunity is also listed under the following categories: